Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Key Facts

Primary Endpoints (CT.gov)

Secondary Endpoints

Eligibility Criteria

Inclusion Criteria: * 1.Voluntary participation with written informed consent obtained prior to any study-specific procedures. * 2.Age ≥ 18 years and ≤ 75 years, regardless of sex. * 3.Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * 4.Life expectancy of at least 3 months. * 5.Histologically or cytologically confirmed small cell lung cancer (SCLC) based on pathology and immunohistochemistry/immunophenotyping results; disease staged as extensive-stage SCLC (ES-SCLC) according to the Veterans Administration Lung Study Group (VALG) staging system. * 6.Disease progression (at the time of enrollment) after at least two cycles of platinum-based systemic therapy with or without PD-1/L1 inhibitors; no more than two prior lines of therapy. Note: Adjuvant therapy is considered one prior line if disease progression occurs during treatment or within 6 months of the last adjuvant dose. * 7.At least one measurable lesion as defined by RECIST version 1.1. Lesions previousl…

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Source